Performance of RNAC Cartesian Therapeutics | -20.6% in 12m
Compare RNAC with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Cartesian Therapeutics with its related Sector/Index XBI
Performance Duell RNAC vs XBI
TimeFrame | RNAC | XBI |
---|---|---|
1 Day | 0.34% | -1.52% |
1 Week | 24.9% | 3.45% |
1 Month | 42.9% | 7.71% |
3 Months | 11.9% | -2.11% |
6 Months | -17.7% | 25.51% |
12 Months | -20.6% | 6.37% |
YTD | 34.5% | 1.05% |
Rel. Perf. 1m | 2.94 | |
Rel. Perf. 3m | 2.69 | |
Rel. Perf. 6m | -3.96 | |
Rel. Perf. 12m | -3.06 |
Is Cartesian Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Cartesian Therapeutics (NASDAQ:RNAC) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -72.10 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RNAC as of May 2024 is 21.63. This means that RNAC is currently overvalued and has a potential downside of -18.16% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RNAC as of May 2024 is 21.63. This means that RNAC is currently overvalued and has a potential downside of -18.16% (Sold with Premium).
Is RNAC a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: RNAC is performing better - Values below 0%: RNAC is underperforming
Compare RNAC with Broad Market Indices
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 23.20% | 37.09% | -35.95% | -49.98% |
US NASDAQ 100 | QQQ | 22.66% | 36.77% | -35.13% | -57.98% |
US Dow Jones Industrial 30 | DIA | 23.49% | 36.69% | -33.13% | -42.65% |
German DAX 40 | DBXD | 25.25% | 37.89% | -34.65% | -37.40% |
UK FTSE 100 | ISFU | 23.35% | 33.06% | -34.52% | -36.00% |
Shanghai Shenzhen CSI 300 | CSI 300 | 23.74% | 38.34% | -20.99% | -12.96% |
Hongkong Hang Seng | HSI | 21.12% | 19.58% | -22.70% | -15.27% |
Japan Nikkei 225 | EXX7 | 24.48% | 43.36% | -29.15% | -32.44% |
India NIFTY 50 | INDA | 21.74% | 38.94% | -35.24% | -49.35% |
Brasil Bovespa | EWZ | 24.41% | 37.62% | -15.83% | -32.96% |
RNAC Cartesian Therapeutics vs. Sectors
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 23.85% | 39.55% | -36.17% | -58.11% |
Consumer Discretionary | XLY | 24.51% | 39.16% | -25.00% | -40.30% |
Consumer Staples | XLP | 24.09% | 36.28% | -31.90% | -26.21% |
Energy | XLE | 23.65% | 41.98% | -31.78% | -45.85% |
Financial | XLF | 23.27% | 35.81% | -40.08% | -53.70% |
Health Care | XLV | 22.96% | 37.18% | -32.67% | -34.13% |
Industrial | XLI | 25.13% | 39.38% | -37.35% | -48.96% |
Materials | XLB | 24.51% | 39.32% | -33.68% | -41.25% |
Real Estate | XLRE | 22.34% | 34.38% | -27.30% | -30.61% |
Technology | XLK | 21.79% | 36.34% | -33.98% | -58.94% |
Utilities | XLU | 23.35% | 29.97% | -35.86% | -33.31% |
Aerospace & Defense | XAR | 24.08% | 34.40% | -33.20% | -44.78% |
Biotech | XBI | 21.40% | 35.15% | -43.17% | -27.00% |
Homebuilder | XHB | 25.17% | 36.52% | -48.17% | -71.48% |
Retail | XRT | 22.77% | 35.40% | -38.50% | -45.82% |
Does Cartesian Therapeutics outperform its market, is RNAC a Sector Leader?
No, over the last 12 months Cartesian Therapeutics (RNAC) made -20.63%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months RNAC made 11.93%, while XBI made -2.11%.
No, over the last 12 months Cartesian Therapeutics (RNAC) made -20.63%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months RNAC made 11.93%, while XBI made -2.11%.
Period | RNAC | XBI | S&P 500 |
---|---|---|---|
1 Month | 42.86% | 7.71% | 5.77% |
3 Months | 11.93% | -2.11% | 6.32% |
12 Months | -20.63% | 6.37% | 29.35% |